Clinical adoption, FDA classification, HIPAA, and 12-18 month health system sales cycles need executive judgment most digital health startups can't afford full-time. A fractional healthcare executive closes that gap without a $300K+ salary commitment.
The Problem
Tech leadership reads clinical skepticism as a UX problem
Most digital health companies are run by technical founders who ship fast and iterate, but physicians and clinical staff don't adopt tools that way. A product that tests well with users but skips clinical validation gets flagged by a chief medical officer or ignored by the care team that was supposed to use it. Without someone who has sat on the clinical side of an EHR rollout, teams keep treating adoption resistance as a training problem instead of a trust problem. The fix isn't a better onboarding flow – it's building credibility with clinicians before the product ever reaches them.
Clinical judgment is missing from the roadmap, not just the sales pitch
Product and go-to-market decisions made without clinical input tend to optimize for engagement metrics that don't map to how care actually gets delivered. A feature that looks like a win in a demo can conflict with clinical workflow, documentation requirements, or liability exposure that only becomes visible after a health system's clinical informatics team reviews it. Startups that add clinical advisors late, after the roadmap is set, spend months retrofitting decisions that should have been made with clinical input from the start.
FDA and HIPAA get handled reactively, after they've already cost a deal
Whether a product needs FDA clearance as Software as a Medical Device, how it's classified, and what HIPAA-compliant infrastructure actually requires are executive-level calls, not engineering tickets. Companies that treat regulatory strategy as something legal handles after the product is built routinely discover the issue during a health system's security and compliance review – the point where a deal stalls or dies. Building the regulatory position early is a competitive advantage; discovering it's missing during procurement is a lost quarter.
Health system procurement runs on relationships technical teams don't have
Selling into a health system means navigating IT security review, clinical informatics sign-off, and a procurement committee that moves on its own 12-18 month timeline – not a sales team's quarter. None of that moves without someone who has been on the buyer's side of that process and has real relationships with clinical and administrative decision-makers. Founders without healthcare executive experience often burn a cycle learning this the hard way: pitching the wrong stakeholder, at the wrong stage, with the wrong proof points.
How We Help
We start by mapping where your current leadership has healthcare gaps: clinical credibility, regulatory strategy, or health system relationships. That means reviewing your product roadmap against clinical workflow requirements, checking where you actually stand on FDA classification and HIPAA infrastructure, and looking at your pipeline to see whether stalled deals are a sales problem or a trust problem with clinical buyers.
From there we place a fractional healthcare executive who has direct experience in your clinical domain – not a generalist consultant, but someone who has run point on FDA submissions, health system contracts, or clinical adoption in a comparable category. They sit in your leadership meetings, weigh in on board materials, and carry decision-making weight on the calls that determine whether a product gets clinical buy-in or gets shelved.
The strategic work is specific: building the regulatory roadmap before it becomes a blocker, shaping the product and go-to-market plan around how care teams actually adopt new tools, and opening doors with health systems and clinical leaders that a technical founder can't open alone. This is where the fractional model earns its keep – you get executive judgment on the decisions that are hardest to reverse once made.
We also build internal capability so the engagement has an end point. That means coaching existing leadership on healthcare-specific decision-making and leaving behind a regulatory and clinical-adoption framework your team can run without us, rather than creating a permanent dependency on an outside executive.
What we deliver
- Healthcare leadership gap assessment against your product roadmap and pipeline
- Fractional healthcare executive embedded in leadership meetings and board materials
- FDA classification and HIPAA infrastructure roadmap built before it blocks a deal
- Health system and clinical relationship development with named decision-makers
- Internal leadership coaching so healthcare judgment doesn't leave when the engagement ends
The digital health companies that stall aren't the ones with weak technology – they're the ones where the first clinical or regulatory conversation happens after the product is already built. Healthcare executive judgment has to be in the room before that point, not brought in to clean up after it.
Our Methodology
The first 30 days are assessment: we review your leadership team, product roadmap, regulatory position, and pipeline to find where the gap actually sits – clinical credibility, FDA/HIPAA readiness, or health system relationships – and select a fractional executive whose background matches that specific gap, not a generic healthcare title.
Days 31-60 are onboarding into real decisions, not observation. Your fractional CXO gets working knowledge of your clinical value proposition and product roadmap fast, then starts weighing in on the regulatory and go-to-market calls already in motion. This is where most of the near-term value shows up, because the executive is correcting course on decisions before they're locked in.
The final 30 days shift toward building what survives the engagement: a regulatory roadmap your team owns, a clinical adoption framework tied to your product cycle, and coaching for existing leadership so the healthcare judgment we brought in doesn't disappear when the fractional executive rolls off.
How We Work
Week one is a leadership and pipeline assessment – what's actually blocking clinical adoption or health system deals, and what executive gap is causing it. Week two we match and onboard a fractional executive whose direct experience fits your clinical domain, not a generalist healthcare hire.
Most engagements run 2-3 days a week initially, with the executive sitting in leadership meetings, board prep, and the specific deals or product decisions that need clinical or regulatory judgment. From your side, that means real access – board materials, pipeline detail, product roadmap – not a summary deck once a month.
We run monthly strategic reviews with quarterly checkpoints against the regulatory and go-to-market plan. Most companies see sharper decision-making on clinical and regulatory calls within the first month, with measurable movement on stalled health system deals or FDA positioning by the second quarter. Initial engagements run 12-18 months, which matches the actual sales and regulatory cycles in this category rather than an arbitrary contract length.
- Faster clinical buy-in on product decisions
- Regulatory roadmap built ahead of health system procurement review
- Movement on stalled health system deals
- Direct relationships with clinical and administrative decision-makers
If your digital health company needs fractional cxo leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does a fractional CXO engagement cost for a digital health company?
Fractional healthcare CXO engagements typically run $20K-35K per month for 2-3 days a week of senior executive time, depending on the executive's background and how much regulatory versus go-to-market work is involved. That's against a $300K+ total comp package for a full-time healthcare executive hire, with none of the recruiting timeline. Most companies see sharper strategic decisions within the first 30-60 days.
How long before we see results from a fractional CXO engagement?
Sharper decision-making on clinical and regulatory calls typically shows up within the first 2-4 weeks, once the executive is in your leadership meetings and pipeline reviews. Movement on stalled health system deals or FDA positioning usually takes 6-8 weeks to materialize. Deeper relationship and partnership development with health systems builds over 6-12 months, which reflects how long those sales cycles actually run.
How does the fractional CXO integrate with our existing leadership team?
They sit in your leadership meetings, weigh in on board materials, and carry real decision-making input on the calls where clinical or regulatory judgment matters – not an outside advisor brought in for occasional opinions. We set clear boundaries upfront on where their authority sits versus your existing team's, so the engagement adds judgment without creating confusion about who owns what decision.
What makes Winston Francois different from a generic fractional executive service?
Most fractional executive firms place generalists who can run a leadership meeting but have never sat through an FDA submission or a health system security review. Our placements have direct experience in the specific regulatory and clinical dynamics of digital health – FDA classification, HIPAA infrastructure, clinical adoption, health system procurement. That's the difference between an executive who can advise on healthcare strategy and one who's actually done it.
How do you measure ROI from a fractional CXO engagement?
We track concrete movement: deals that were stalled in health system procurement and moved forward, regulatory milestones hit on schedule, and whether clinical stakeholders are engaging with the product differently. We review this against the roadmap set in the first 30 days, not a general satisfaction check-in. Most companies see measurable pipeline or regulatory movement within 60-90 days.
What type of digital health company is the right fit for this service?
Companies with working technology and early clinical traction, usually Series A-B with $3M-25M ARR, who are hitting a wall in health system sales, regulatory strategy, or clinical adoption that their current team can't clear alone. If you can't yet justify a full-time healthcare executive hire but the gap is costing you deals, that's the fit. We start by mapping exactly where the gap sits before proposing an engagement.
